Video

Aaron Boster from OhioHealth: Extended Data On Lemtrada Shows More Good News

Author(s):

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including lemtrada.

As more and more treatments are approved for patients with multiple sclerosis questions are being answered about their effectiveness long past their approval dates. This is true for many of the medications including Lemtrada.

Aaron Boster, MD, from OhioHealth discussed the latest data being presented on the medication at the annual ECTRIMS conference in London. Unlike other treatments which are taken daily, weekly, or monthly Boster noted Lemtrada is given in much more extended durations and has shown to be effective for much longer periods of time. Many patients, he noted, do not need any further treatment after a second dose of the medication.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.